HGEN - Long COVID the newest target of vaccine and drug developers

Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long COVID globally. Long COVID is marked by hundreds of different symptoms, including conditions such as fatigue, chest pain, and brain fog lasting more than three months. It affects people who had both mild and severe COVID-19, including children. Leading developers of COVID-19 vaccines and therapeutics are in the early discussions with scientists on how to address the disease, which affects an estimated 1-in-7 working-age adults, according to Reuters. Moderna (NASDAQ:MRNA) is donating its COVID-19 vaccine for early U.K.-based testing to determine if the mRNA-based shot can spring the immune system into action and address the long COVID symptoms, the news agency reported citing a company statement. Meanwhile, Xarelto (rivaroxaban), a blood

For further details see:

Long COVID, the newest target of vaccine and drug developers